Pharmafile Logo
Pharmafocus logo
Advanced Search

Merck

Showing 15 posts of 360 posts found.

FDA approves Merck’s Capvaxive for prevention of pneumococcal disease

June 18, 2024
Medical Communications Capvaxive, FDA, Infections and infestations, Merck, pneumonia

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

News

Merck to acquire EyeBio for an upfront $1.3bn

May 31, 2024
Business Services EyeBio, Merck, Opthalmology, acquisition, ophthalmology

Merck, known as MSD outside of the US and Canada, and EyeBiotech Limited, have announced that the two companies have …

News

Merck shares data from phase 3 trial of Keytruda for TNBC treatment

May 29, 2024
Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda

Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …

News

Merck to acquire Mirus Bio for $600m

May 23, 2024
Business Services Merck, Pharmacy, acquisition, gene therapies

Merck has announced that it has signed a definitive agreement to acquire Mirus Bio for $600m.

News

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024
Research and Development Gastric, MSD, Merck, Oncology, keytruda

Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …

News

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

April 10, 2024
Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer

TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …

News

FDA approves Merck’s Winrevair for PAH treatment

March 27, 2024
Medical Communications Cardiology, FDA, Merck, Winrevair, pulmonary arterial hypertension

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

News

Merck shares results for Keytruda in cervical cancer treatment

March 18, 2024
Research and Development Merck, Oncology, cervical cancer, keytruda, women's health

Merck, known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-A18 trial, …

News

Merck plans to conduct trials for HPV vaccines

March 13, 2024
Research and Development Immunology, Merck, vaccines

Merck, known as MSD outside of the US and Canada, has announced that it is planning to initiate clinical development …

News

Merck completes acquisition of Harpoon Therapeutics for $650m

March 12, 2024
Business Services Harpoon Therapeutics, Merck, Oncology, lung cancer

Merck, known as MSD outside of the US and Canada, has announced that it has completed the acquisition of Harpoon …

News

Gilead and Merck share data from phase 2 trial of HIV treatment

March 7, 2024
Research and Development Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 …

News

Merck to acquire Harpoon Therapeutics for approximately $680m

January 10, 2024
Business Services Harpoon Therapeutics, MSD, Merck, Oncology, acquisition

Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a …

News
markus-spiske-hvsr_cvecvi-unsplash

Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics

December 20, 2023
Research and Development AI diagnostics, Cancer, MSD, Merck, Oncology, Owkin

Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a …

News

Merck and Moderna initiate phase 3 study of NSCLC treatment

December 13, 2023
Medical Communications Merck, Moderna, NSCLC, Oncology, clinical trial

Merck (known as MSD outside of the US and Canada) and Moderna have announced the initiation of the phase 3 …

News

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023
Research and Development AI, Acceleration Consortium, Merck, Pharmacy, experimentation

Merck and the Acceleration Consortium have announced their AI-driven experimentation planner Bayesian Back End (BayBE) is now available open-source on …

News

Latest content

Gilead shares phase 3 results from HIV prevention trial

June 21, 2024

Sarepta Therapeutics gains expanded FDA approval for DMD treatment

June 21, 2024

FDA approves AbbVie’s Skyrizi for UC treatment

June 20, 2024

Takeda shares data from phase 3 trial of CIPD treatment

June 20, 2024

EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment

June 19, 2024